- Home
- MA vs JNJ Comparison
MA vs JNJ Comparison
Compare MA & JNJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MA | JNJ |
|---|---|---|
| Founded | 1966 | 1886 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 483.7B | 542.4B |
| IPO Year | 2005 | 2003 |
Fundamental Metrics
Financial Performance| Metric | MA | JNJ |
|---|---|---|
| Price | $655.54 | $272.59 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 40 | 23 |
| Target Price | ★ $707.79 | $279.41 |
| AVG Volume (30 Days) | 3.2M | ★ 7.2M |
| Earning Date | 10-29-2026 | 10-13-2026 |
| Dividend Yield | 0.52% | ★ 1.94% |
| EPS Growth | 18.93 | ★ 90.50 |
| EPS | ★ 14.59 | 4.49 |
| Revenue | ★ $32,791,000,000.00 | N/A |
| Revenue This Year | $13.93 | $7.46 |
| Revenue Next Year | $12.63 | $6.45 |
| P/E Ratio | ★ $46.04 | $61.60 |
| Revenue Growth | ★ 16.42 | N/A |
| 52 Week Low | $464.52 | $185.12 |
| 52 Week High | $673.50 | $282.02 |
Technical Indicators
Market Signals| Indicator | MA | JNJ |
|---|---|---|
| Relative Strength Index (RSI) | 74.94 | 61.10 |
| Support Level | $554.62 | $262.26 |
| Resistance Level | N/A | $276.92 |
| Average True Range (ATR) | 12.23 | 6.00 |
| MACD | 4.16 | 1.55 |
| Stochastic Oscillator | 98.80 | 82.68 |
Price Performance
Historical ComparisonAbout MA Mastercard Incorporated
Mastercard is the second-largest payment processor in the world, having processed close to $11 trillion in volume during 2025. Mastercard operates in over 200 countries and processes transactions in over 150 currencies.
About JNJ Johnson & Johnson
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.